Curocell is a cell therapy company that discovers and develops CAR-T therapies for cancer. The company's current efforts focus on unleashing the body’s immune system through broad-spectrum CAR-T technologies to treat blood cancers, as well as solid cancers. The company's programmed T cell product candidates are differentiated by incorporation of T cell modifying technology designed to effectively overcoming the immune suppression, and thereby offers greater efficacy compared to the current CAR-T cell technology.
Company Details
- Employees
- 26
- Founded
- -
- Address
- 48 ,yuseong-Daero 1184beon-Gil, Yuseong-Gu, Daejeon,-- Select One -- 34109,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.curocellbtx.com/
- Keywords
- CAR-T, Immune cell therapy, T cell.
- HQ
- Daejeon, -- Select One --
Curocell Questions
Curocell's website is https://www.curocellbtx.com/
Curocell's LinkedIn profile is https://kr.linkedin.com/company/curocell
Curocell has
26 employees.
View email and phone details for 26
employees at Curocell.
Curocell's industry is
Biotechnology Research
Curocell's top competitors are
Korea Biomedical Review,
財團法人醫藥品查驗中心 (Center For Drug Evaluation, Cde),
Tomocube, Inc.,
Allogene Therapeutics,
Genexine, Inc.,
Genuv,
Cha Bio Group｜차바이오그룹,
Alteogen,
Special Care Medical Inc,
Tj Biopharma.
Curocell's categories are Biotechnology Research
Curocell's founding year is 2016
